AI-Enhanced Optimization of Acute Levodopa Challenge Test

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age50-75
SponsorBeijing Tiantan Hospital

About this trial

A quantitative evaluation method was developed for Parkinson's disease and other atypical parkinonism by integrating an innovative motor paradigm with perception technologies and artificial intelligence. Combined with traditional motor paradigms and the acute levodopa challenge test, this study aims to identify diagnostic cut-off values for PD and other atypical parkinonism, explore digital biomarkers for early and differential diagnosis, and establish a corresponding diagnostic model.

Eligibility criteria

Qualifiers

Parkinson's disease (PD) group: 1. Patients with confirmed Parkinson's disease diagnosed based on the 2015 International Movement Disorder Society (MDS) Parkinson's Disease Diagnostic Criteria; 2. Patients with early-stage PD meet the Hoehn-Yahr score ≤ 2.5 points, and patients with intermediate and advanced PD meet the Hoehn-Yahr score of 2.5-5 points; 3. Subjects are 50-75 years old (including boundary values), gender is not limited; 4. Agree to undergo study-related examination evaluation and sign informed consent.

Multiple system atrophy (MSA) group : 1. Patients with confirmed or probable MSA diagnosed based on the diagnostic criteria for MSA published by the International Movement Disorder Society (MDS) in 2022 ;2. Subjects are 50-75 years old (including boundary values), gender is not limited; 3. Agree to undergo study-related examination evaluation and sign informed consent.

Progressive supranuclear palsy (PSP) group: 1. Patients with confirmed or probable PSP diagnosed based on the diagnostic criteria of the 2017 International Movement Disorder Association PSP Collaborative Group; 2. Subjects are 50-75 years old (including boundary values), gender is not limited; 3. Agree to undergo study-related examination evaluation and sign informed consent.

Vascular parkinsonism (VP) group: 1. In line with the diagnostic recommendations of vascular parkinsonism in accordance with the 2004 International Association for Movement Disorders and the 2017 Chinese expert consensus; 2. Subjects are 50-75 years old (including boundary values), gender is not limited; 3. Agree to undergo study-related examination evaluation and sign informed consent.

Disqualifiers

Cognitive dysfunction, unable to complete the study (MMSE < 23)

Inability to tolerate levodopa shock test

Patients with failure of important organs (heart, lung, liver, kidney, etc.), malignant tumors, unstable conditions and other serious internal diseases

Those with serious behavioral problems or mental disorders

Trial design

Treatments tested in this trial

  • video recording

Treatment groups

2,000 Participants
are divided into 7 treatment groups

7

Treatment groups

See each treatment group below.

Sponsors and collaborators

Beijing Tiantan Hospital

Lead sponsor

Ruijin Hospital

Collaborator

Nanjing Medical University

Collaborator

Second Affiliated Hospital of Soochow University

Collaborator

Beijing Hospital

Collaborator

Fujian Medical University Union Hospital

Collaborator

Guangdong Provincial People's Hospital

Collaborator

West China Hospital

Collaborator

The First Affiliated Hospital of Dalian Medical University

Collaborator

China-Japan Union Hospital, Jilin University

Collaborator

Renmin Hospital of Wuhan University

Collaborator

First Affiliated Hospital of Chongqing Medical University

Collaborator

Second Affiliated Hospital of Nanchang University

Collaborator

Xijing Hospital

Collaborator

The Affiliated Hospital of Qingdao University

Collaborator

The Second Affiliated Hospital of Xinjiang Medical University

Collaborator

Shenzhen People's Hospital

Collaborator

Tianjin Medical University General Hospital

Collaborator

Qilu Hospital of Shandong University

Collaborator

The First People's Hospital of Yunnan

Collaborator

The First Hospital of Jilin University

Collaborator

Tianjin Huanhu Hospital

Collaborator

The First Affiliated Hospital of Anhui Medical University

Collaborator

Wannan Medical College Yijishan Hospital

Collaborator

The Affiliated Hospital of Xuzhou Medical University

Collaborator